Figure 3. Involvement of cannabinoid-activated receptors in inhibition of IL-1β-induced TF protein expression by WIN 55,212-2.

Effect of AM-251 (CB₁ antagonist), AM-630 (CB₂ antagonist) and capsazepine (Capsa, TRPV1 antagonist) on the WIN 55,212-2-mediated inhibition of IL-1β-induced TF protein expression (A) or basal and IL-1β-induced TF protein levels (B). Cells were pretreated with the respective receptor antagonist (all tested at a final concentration of 1 μM) for 1 h. IL-1β (10 ng/ml), WIN 55,212 2 (10 μM) or vehicle were added subsequently and the incubation was continued for 8 h. (C) Effect of the cannabinoid receptor-inactive enantiomer WIN 55,212-3 on basal and IL-1β-induced TF protein expression. Cells were incubated with equimolar concentrations of WIN 55,212-3 and WIN 55,212-2 (both at 10 μM) for 8 h. Percent control represents comparison with vehicle-treated cells (100%) in the absence of test substance. Values are means + SEM of n = 3 per group. ***P < 0.001 vs. corresponding vehicle control; ^#P < 0.05, ^###P < 0.001 vs. IL-1β, ANOVA plus post hoc Bonferroni test.